Table 2.

APOBEC3B expression in cervical cancer patients with clinical characteristics

Characteristic	Low expression of APOBEC3B	High expression of APOBEC3B	P
n	153	153
T stage, n (%)			0.008*
T1	56 (23%)	84 (34.6%)
T2	40 (16.5%)	32 (13.2%)
T3	15 (6.2%)	6 (2.5%)
T4	7 (2.9%)	3 (1.2%)
N stage, n (%)			0.838
N0	60 (30.8%)	74 (37.9%)
N1	29 (14.9%)	32 (16.4%)
M0	52 (40.9%)	64 (50.4%)
M1	9 (7.1%)	2 (1.6%)
Clinical stage, n (%)			0.349
Stage I	74 (24.7%)	88 (29.4%)
Stage II	37 (12.4%)	32 (10.7%)
Stage III	24 (8%)	22 (7.4%)
Stage IV	14 (4.7%)	8 (2.7%)
Primary therapy outcome, n (%)			<0.001*
PD	20 (9.1%)	3 (1.4%)
SD	2 (0.9%)	4 (1.8%)
PR	6 (2.7%)	2 (0.9%)
CR	78 (35.6%)	104 (47.5%)

^* P<0.05.